SCHEMBL30977733

SCHEMBL30977733

CCCCCCCCC(CCCCCC)C(=O)OCCCCCC(CCCCCSCC(CCCCCC)OC(=O)CCCCC(C)C)NCCCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TLR2 O60603 20/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31035789 0.97 TLR2 (0.38) TLR2
SCHEMBL30837942 0.93 TLR2 (0.39) TLR2
SCHEMBL30838052 0.93 TLR2 (0.39) TLR2
SCHEMBL30837985 0.93 TLR2 (0.39) TLR2
SCHEMBL30977705 0.93 TLR2 (0.39) TLR2
SCHEMBL30977723 0.93 TLR2 (0.39) TLR2
SCHEMBL30837973 0.93 TLR2 (0.39) TLR2
SCHEMBL30837891 0.93 TLR2 (0.39) TLR2
SCHEMBL30837944 0.93 TLR2 (0.39) TLR2
SCHEMBL30837979 0.93 TLR2 (0.39) TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638417-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS Nanovation Therapeutics Inc. (CA) 2025-10-29 — — EP disclosed
US-20240398977-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-12-05 — — US disclosed
US-12121591-B2 Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents NANOVATION THERAPEUTICS INC. (CA) 2024-10-22 — — US disclosed
US-20240261430-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-08-08 — — US disclosed
WO-2024130421-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12121591-B2 Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents SLC43A1, NSUN3, NSUN2 TLR2 3615/4885
US-20240261430-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS SLC43A1, NSUN3, NSUN2 TLR2 3615/4885
US-20240398977-A1 SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS SLC43A1, NSUN3, NSUN2 TLR2 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback